DexTech receives positive results regarding multiple myeloma
1 February, 2021
DexTech can announce that the company is expanding its preclinical program to also include research into the effect of OsteoDex on multiple myeloma, (MM), in vitro, cell cultures. MM is a malignant tumor disease of the bone marrow, which causes the skeleton to break down. MM is an incurable disease where a number of different treatments are used to slow down the process. The treatments often have severe side effects.
The company sees OsteoDex as very promising for the treatment of MM based on its mechanism of action and mild side effects. In summary, a potent treatment effect is seen, even at low concentrations of OsteoDex. Effect at low concentration is an important result in in vitro testing and indicates possible effect in vivo (in living organism). The observed cell killing effect is superior to the compared substance, Melphalan, which is a standard drug in the treatment of MM.
The investment is made as an important part of the Company’s strategy to broaden interest in OsteoDex’s opportunities, excluding prostate cancer, and as a targeted part of the strategy for out-licensing. Despite delays due to the Corona pandemic, the company looks forward with great confidence to the continued work in 2021.
For further information
Gösta Lundgren – CFO & Investor Relations
DexTech Medical AB
Phone: +46 (0) 707104788
This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the above contact person, for publication on February 1, 2021.